MRK

Merck & Co., Inc. (MRK) KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

1 month ago

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

1 month ago

Merck & Co., Inc. (NYSE: MRK) Q4 2025 Earnings Conference

2 months ago

Merck & Co., Inc. (NYSE: MRK) Q4 2025 Earnings Call dated Feb. 03, 2026 Corporate Participants: Robert Davis — Chairman…

2 months ago

Merck & Co., Inc. (NYSE: MRK) Q2 2025 Earnings Call dated Jul. 29, 2025 Corporate Participants: Peter Dannenbaum — Senior…

2 months ago

Merck & Co., Inc. (NYSE: MRK) Q3 2025 Earnings Call dated Oct. 30, 2025 Corporate Participants: Peter Dannenbaum — Senior…

5 months ago

Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion…

1 year ago

Merck (NYSE: MRK) reported its third quarter 2024 earnings results today. Sales grew 4% year-over-year to $16.7 billion. Excluding FX,…

2 years ago

Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported net profit for the second quarter of 2024, on an adjusted…

2 years ago

Merck (NYSE: MRK) reported sales of $16 billion for the third quarter of 2023, up 7% from the same period…

3 years ago

Merck (NYSE: MRK) reported second quarter 2023 earnings results today. Total worldwide sales were $15 billion, up 3% from the…